Floatz logo

C-Car066

B Cell Lymphoma

National Cancer Institute (NCI)Phase 1/2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
81/ 100

Competitive context

22 Active assets in the B Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Zanubrutinib
The First Affiliated Hospital of Soochow University
Phase 4BBB
Chimeric Antigen Receptor Modified T Cells Infusion
The First Affiliated Hospital of Soochow University
Phase 2/3BB
VINCRISTINE SULFATE
The First Affiliated Hospital of Soochow University
Phase 4BB
Cart-19 And 20 Cells
Henan Cancer Hospital
Phase 2BB
Cart-19 Cells
Shenzhen BinDeBio Ltd.
Phase 2/3BB

View all 50 →

Same molecule, other indications

C-Car066 is also rated in:

B-cell chronic lymphocytic leukemiaDormant
BB
Indicative ·
67 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →